Downregulation of CPLX1 is associated with impaired basal synaptic strength and short‐term plasticity (Chang et al., 2015), and more recently decreased CPLX1 levels have been suggested as a significant risk factor associated with AD and Parkinson's disease (Lahut et al., 2017; Ramos‐Miguel et al., 2017). This evidence concerns the gene CPLX1 and Alzheimer disease.